Daphnetin induced differentiation of human renal carcinoma cells and its mediation by p38 mitogen-activated protein kinase

Biochemical Pharmacology

Volumn 67, Issue 9, 2004, Pages 1779-1788

  Finn, Gregory J ^a   Creaven, Bernadette S ^a   Egan, Denise A ^a  

^a DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

Author keywords

Dimethylsulphoxide; DMEM; DMSO; Dulbecco's modified Eagle's medium; ERK; Extracellular signal related kinase; MAPK; MDR; Mitogen activated protein kinase; Multi drug resistence; P glycoprotein; P gp; RCC; Renal cell carcinoma; SAPK; Stress activated protein kinase

Indexed keywords

CYTOKERATIN 18; DAPHNETIN; GLYCOPROTEIN P; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN INHIBITOR; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL MATURATION; CONCENTRATION (PARAMETERS); DRUG EFFECT; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

CARCINOMA, RENAL CELL; CELL CYCLE; CELL DIFFERENTIATION; DRUG RESISTANCE, MULTIPLE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; P-GLYCOPROTEIN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; TUMOR CELLS, CULTURED; UMBELLIFERONES;

EID: 1842785873     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.01.014     Document Type: Article

References (65)

1. Lake B.G. Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. Food Chem. Toxicol. 37:1999;423-453.
2. Estevez-Braun A., Gonzalez A.G. Coumarins Natural Prod. Rep. 2:1997;465-475.
3. Egan D.A., O'Kennedy R., Moran E., Cox D., Prosser R., Thornes R.D. The pharmacology, metabolism, analysis and applications of coumarin and coumarin related compounds. Drug. Metab. Rev. 22:1990;503-529.
4. Cox D., O'Kennedy R., Thornes R.D. The rarity of liver toxicity in patients treated with coumarin (1,2-benzopyrone). Hum. Toxicol. 88:1989;501-506.
5. Hoult J.R.S., Paya M. Pharmacological and biological actions of simple-coumarins: natural products with therapeutic potential. Gen. Pharm. 27(4):1996;713-722.
6. Casley-Smith JR, Casley-Smith JR. In: O'Kennedy R, Thornes RD, editors. Coumarins. Biology, applications and mode of action. Chichester, UK: John Wiley; 1997. p. 148-85.
7. Jamal S., Casley-Smith J.R., Casley-Smith J.R. The effects of 5,6-benzo-pyrone (coumarin) and DEC on filaritic lymphoedema and elephantitus in India. Ann. Trop. Med. Parasit. 83:1989;287-296.
8. Lu H.Q., Schmitz U., Niggemann B., Zanker K.S. Computer assisted molecular design for the determination of structure activity relationships for chemotherapeutic agents. Ann. N.Y. Acad. Sci. 833:1997;147-153.
9. Piller NB. In: O'Kennedy R, Thornes RD, editors. Coumarins. Biology, applications and mode of action. Chichester, UK: John Wiley; 1997. p. 185-200.
10. Flanigan R. Should radical nephrectomy be performed in the face of surgically incurable disease. Curr. Opin. Urol. 10:2001;429-439.
11. Vucky J., Motzer R.J. Cytokine therapy in renal cell cancer. Urol. Oncol. 5:2000;249-257.
12. Broghammer E.L., Ratliff T.L. Immunotherapy of urological tumours: principles and progress. Urol. Oncol. 7:2002;45-56.
13. Stefanelli C., Tantini B., Fattori M., Stanic I., Pignatti C., Clo C.et al. Caspase activation in etoposide-treated fibroblasts is correlated to ERK phosphorylation and both events are blocked by polyamine depletion. FEBS Lett. 527:2002;223-228.
14. Cobb M.H. MAP kinase pathways. Prog. Biophys. Mol. Biol. 71:1999;479-500.
15. Cross J.V., Deak J.C., Rich E.A., Qian Y., Lewis M., Parrott L.A.et al. Serine/threnoine protein kinases and apoptosis. J. Biol. Chem. 274(4):1999;31150-31154.
16. Ozaki I., Tani E., Ikemoto H., Kitagawa H., Fujikawa H. Activation of stress-activated protein kinase c-jun terminal kinase and p38 kinase in calphostin c induced apoptosis requires caspase-3-like proteases but is dispensable for cell death. J. Biol. Chem. 7(9):1999;5310-5317.
17. Fan M., Du L., Stone A.A., Gilbert K., Chambers T.C. Modulation of mitogen-activated protein kinases and phosphorylation of Bcl-2 by vinblastine represent persistent forms of normal fluctuations at G2M. Cancer Res. 269:2000;31234-31242.
18. Finn G., Creaven B., Egan D. In vitro cytotoxic potential and mechanism of action of selected coumarins, using human renal cell lines. Cancer Lett. 183:2002;61-68.
19. Tian W., Zhang Z., Cohen D.M. MAPK signallling and the kidney. Am. J. Renal Physiol. 279:2000;F593-F604.
20. Oka H., Chantani Y., Hoshino R., Ogawa O., Kakehi Y., Terachi T.et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal renal cell carcinoma. Cancer Res. 55(18):1995;4182-4187.
21. Montesano R., Soriano J.V., Hosseini G., Pepper M.S., Schramek H. Constitutively active mitogen-activated protein kinase kinase MEK1 disrupts morphogenesis and induces an invasive phenotype in Madin-Darby canine kidney epithelial cells. Cell Growth Differ. 10:1999;317-332.
22. Motzer R.J., Bander N.H., Nanus D.N. Renal-cell carcinoma. N. Engl. J. Med. 335:1996;865-875.
23. Krishna R., Mayer L. Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Arch Pharm. 334(4):2000;157-162.
24. Mertins S., Hollingswood M., Dykes D., Bodde E., Tsai C., Jefferies C.A.et al. Screening for and identification of novel agents directed at renal cell carcinoma. Clin. Cancer Res. 7:2001;620-633.
25. Teodori E., Scapecchi S., Gualteri F. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Il Farm. 57:2002;385-415.
26. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
27. Ling V., Thomson L.H. J. Cell Physiol. 83(1):1974;103-106.
28. Carmichael J., De Graf G., Gadzar A., Minna J., Mitchell J. Evaluation of a tetrazolium-based colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:1987;936-942.
29. Doige C.A., Sharom F.J. Strategies for the purification of P-glycoprotein from multi-drug resistant Chinese ovary cells. Protein Expr. Purif. 2:1991;256-265.
30. Lewis T.S., Shapiro P., Ahn N.G. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74:1998;49-139.
31. 2+ and calmodulin. Cell Signal. 14:2002;649-654.
32. Okano J., Rustgi K. Paclitaxel induces prolonged activation of the Raf/MEK/ERK pathway independently of activating the programmed cell death machinery. J. Biol. Chem. 276(22):2001;19555-19564.
33. Mielke K., Herdegen T. JNK and p38 stress-kinases - degenerative effectors of signal transduction-cascades in the nervous system. Prog. Neurobiol. 61:2000;45-60.
34. Morooka T., Nishida E. Requirement of p38 mitogen-activated protein kinase for neuronal differentiation in PC12 cells. J. Biol. Chem. 273:1998;24285-24288.
35. Ono K., Han J. The p38 signal transduction pathway activation and function. Cell Signal. 12:2000;1-13.
36. Grana X., Premkumar E. Cell cycle control in mammalian cells: roles of cyclins, cyclin dependent kinases, growth supressor genes and cyclin dependent kinase inhibitors. Oncogene. 11:1995;211-219.
37. Standheim T.A., Xiao H., Eastmann A. Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated Ml-1 cells. Cancer Res. 61:2001;1533-1540.
38. Zhan Y., Van de Water B., Wang Y., Stevens J.L. The roles of caspase-3 and Bcl-2 in chemically induced apoptosis but not necrosis of renal epithelial cells. Oncogene. 18:1999;6505-6512.
39. Walczak J., Wood H., Wilding G., Williams T., Bishop C.W., Carducci M. Prostate cancer prevention strategies using antiproliferative or differentiating agents. Urology. 57:2001;81-85.
40. Englaro W., Rezzonic R., Durand-Clement M., Lallemand D., Ortonne J.P., Bollotti R. Mitogen-activated protein kinase pathway and AP-1 are activated during cAMP-induced melanogenesis in B-16 melanoma cells. J. Biol. Chem. 270(41):1995;24315-24320.
41. Smalley K., Eisen T. The involvement of P38 mitogen-activated protein kinase in the alpha-melanocyte stimulating hormone induced melanogenic and anti-proliferative effects in B16 murine melanoma cells. FEBS Lett. 476:2000;198-202.
42. Gottesmann M.M., Pastan I., Ambukar S.V. P-glycoprotein and multidrug resistance. Curr. Opin. Gene. 6:1996;610-617.
43. Tellingen O.V. The importance of drug-transporting P-glycoproteins in toxicology. Toxicol. Lett. 120:2001;31-41.
44. Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 163:2000;408.
45. Ulhman D.L., Nguyen P.L., Manivel J.C. Association of immunohistochemical staining for p53 and with metastatic progression and poor survival in patients with renal cell carcinoma. J. Natl. Cancer Inst. 86:1994;1470-1475.
46. Malek Z., Swope V., Suzuki I., Akali C., Harriger M.D., Boyces S.T.et al. Mitogenic and melanogenic stimulation of normal human melanocytes by melantrophic peptides. Proc. Natl. Acad. Sci. U.S.A. 92:1995;1789-1793.
47. Busca R., Berlotto J., Ballotti R. Inhibition of the phosphatidylinositol 3-kinase/p70s6-kinase pathway induces B16 melanoma cell differentiation. J. Biol. Chem. 271(50):1996;31824-31830.
48. Englaro W., Berlotto C., Busca R., Brunet A., Pages G., Ortonne J.et al. Inhibition of the mitogen-activated protein kinase pathway triggers B16 melanoma cell differentiation. J. Biol. Chem. 273(16):1998;9966-9970.
49. Cuenda A., Cohen P. Stress activated protein kinase, p38 and a rapamycin sensitive pathway are required for C2C12 myogenesis. J. Biol. Chem. 274:1999;4341-4346.
50. Engelmann J.A., Berg A.H., Lewis R.Y., Lin A., Lisanti M.P., Scherer P.E. Constitutively active mitogen-activated protein kinase kinase 6 or salicylate induces 3T3 L1 adipogenesis. J. Biol. Chem. 274:1999;35630-35638.
51. Park H.E., Gilchrist B.A. Signalling pathways mediating melanogenesis. Cell Mol. Biol. 45(7):1999;919-930.
52. Nebreda A.R. p38 MAP kinases: beyond the stress responses. TIBS. 25:2000;57-260.
53. Hagemann C., Blank J. The ups and downs of MEK kinase interactions. Cell Signal. 13:2001;863-875.
54. Leszczyniecka M., Roberts T., Dent P., Grant S., Fisher P.B. Differentiation therapy of human cancer: basic science and clinical applications. Pharm. Therap. 90:2001;105-106.
55. Gandarillas A. Epidermal differentiation. Exp. Gener. 35:2000;53-62.
56. Freshney RI. Culture of animal cells: a manual of basic technique. Chichester, UK: John Wiley; 2000. p. 220-7.
57. King RJB. Cancer biology. England: Prentice-Hall; 2000. p. 146-60.
58. Hoffmannova J., Kozubik A., Dusek L., Pachernik J. Inhibitors of lipoxygenase metabolism exert synergistic effects with retinoic acid on differentiation of human leukaemia HL-60 cells. Eur. J. Pharmacol. 350:1998;273-284.
59. Moll R., Franke W.W., Schiller D.L. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 31:1982;11-245.
60. Leader M., Patel J., Makin C., Henry K. An analysis of the sensitivity and specificity of the cytokeratin marker CAM 5.2 for epithelial tumours. Results of a study of 203 sarcomas, 50 carcinomas and 28 malignant melanomas. Histopathology. 10:1986;1315-1324.
61. Jing Y., Zhang J., Wazman S., Mira-y-Lopez R. Up-regulation of cytokeratins 8 and 18 in human breast cancer T47D cells is retinoid-specific and retinoic acid receptor dependent. Differentiation. 60(2):1996;109-117.
62. Agarwal C., Sharma Y., Zhao J., Agarwal R. A polyphenolic fraction from grape seeds causes irreversible growth inhibition of breast carcinoma MDA-MB468 cells by inhibiting mitogen-activated protein kinases activation and inducing G1 arrest and differentiation. Clin. Cancer Res. 6:2000;2921-2930.
63. Goldstein L.J., Galski H., Fojo A., Willingham M., Lai S., Gadzar A.et al. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 81:1989;116-124.
64. Yang E.B., Zhoa N.Y., Zhand K., Mack P. Daphnetin, one of coumarins derivatives is a protein kinase inhibitor. Biochem. Biophys. Res. Comm. 260:1999;682-685.
65. Wosikowski K., Schuurhuris D., Johnson K., Paull K.D., Myers T.G., Weinstein J.N.et al. Identification of epidermal growth factor receptor and c-erb-2 pathway inhibitors by correlation with gene expression patterns. J. Natl. Cancer Inst. 89:1997;1505-1515.